Genitourinary Cancer

Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors

Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors

By

Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.

Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer

Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer

By

Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.

Hemodialysis Indicative of Higher Mortality After Bladder Cancer Surgery

Hemodialysis Indicative of Higher Mortality After Bladder Cancer Surgery

By

Patients on hemodialysis that underwent radical cystectomy for bladder cancer experienced increased mortality.

Delirium Screening Tool Found Effective for Nurse Assessment of Delirium in Surgical Patients

Delirium Screening Tool Found Effective for Nurse Assessment of Delirium in Surgical Patients

By

After assessing and addressing nurse knowledge of use of the Confusion Assessment Method (CAM) tool, implementation of screening protocol improved interventions for older hospitalized patients who had undergone urological surgery. These results were presented in a poster at the NACNS 2018 Annual Conference.

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

By

Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

By

Investigators compared adjuvant gemcitabine plus cisplatin vs surveillance and subsequent chemotherapy if needed for patients who underwent nephron-ureterectomy for UTUC.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Atezolizumab Has Some Benefits in Urothelial Carcinoma, But OS Not Improved

Atezolizumab Has Some Benefits in Urothelial Carcinoma, But OS Not Improved

By

In the IMvigor 311 trial, researchers sought to determine if atezolizumab improves overall survival for patients with metastatic urothelial carcinoma vs physicians' choice of 3 IV regimens.

Cardiopulmonary Fitness Leads to Better Outcomes in Bladder Cancer Surgery

Cardiopulmonary Fitness Leads to Better Outcomes in Bladder Cancer Surgery

By

A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.

Age, Race, Sex Affect Survival for Patients With HPV-Associated Cancers

Age, Race, Sex Affect Survival for Patients With HPV-Associated Cancers

By

Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.

First-line Pembrolizumab May Be Efficacious for Cisplatin-ineligible Urothelial Cancer

First-line Pembrolizumab May Be Efficacious for Cisplatin-ineligible Urothelial Cancer

By

Approximately 50% of patients with advanced urothelial carcinoma are unable to receive standard first-line cisplatin-based chemotherapy, indicating a need for additional treatment options.

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

By

Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.

Use of Checkpoint Inhibitors in Urothelial Carcinoma

Use of Checkpoint Inhibitors in Urothelial Carcinoma

By

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

Metabolic Syndrome More Likely After Platinum-Based Chemotherapy for Testicular Cancer

Metabolic Syndrome More Likely After Platinum-Based Chemotherapy for Testicular Cancer

By

Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.

Nivolumab Approved for Locally Advanced or Metastatic Bladder Cancer

Nivolumab Approved for Locally Advanced or Metastatic Bladder Cancer

By

The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.

How We Developed a New Protocol for Treatment of Urethral Carcinoma

How We Developed a New Protocol for Treatment of Urethral Carcinoma

Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.

Nivolumab Monotherapy Active in Recurrent Metastatic Urothelial Carcinoma

By

Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.

Mycobacteria Treatment for Bladder Cancer More Effective With Emulsification in Olive Oil

By

Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.

Researchers Estimate Familial Prostate Cancer Risk

Researchers Estimate Familial Prostate Cancer Risk

By

Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.

Functional Status Linked to Treatment Choice for Prostate Cancer

Functional Status Linked to Treatment Choice for Prostate Cancer

By

Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.

<i>BRCA1</i> Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

BRCA1 Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.

Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma

Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma

By

US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.

More Than HPV Vaccine Uptake Is Needed to Reduce the Burden of HPV-associated Cancers

More Than HPV Vaccine Uptake Is Needed to Reduce the Burden of HPV-associated Cancers

By

Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.

Radiation Therapy Better Than Chemotherapy for Stage IIA Testicular Cancer

By

Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.

Well Water a Suspected Cause of Bladder Cancer in New England

Well Water a Suspected Cause of Bladder Cancer in New England

Researchers believe arsenic exposure might contribute to higher-than-normal rates of bladder cancer in the region.

Risk of Bladder Cancer Higher for Patients Taking a Specific Diabetes Medication

By

Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.

Certain Cancer Surgeries Increase Risks for Injuries and Other Health Concerns in Older Patients

By

Older patients who undergo surgery to treat cancer are more likely to experience injuries and other health issues such as falling down, breaking bones, dehydration, bed sores, failure to thrive, and delirium. The risks are particularly notable in patients who undergo major abdominal surgery.

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

By

Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.

Mental Health Status May Impact Bladder Cancer Surgery Outcomes

By

Mental health status prior to bladder cancer surgery may be associated with postoperative outcomes.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs